I bring you Shockwave Eréctil Disfuncione, the device that redefines ED therapy for medical clinics. Our High-Quality system uses patented radial shockwave technology, delivering precise energy pulses to promote neovascularization and tissue healing. I designed it for easy integration into a busy urology practice, with a compact footprint, intuitive touchscreen, and fast treatment protocols. From a buyer’s view, this means higher patient throughput, better outcomes, and predictable ROI for your Company. Our warranty, service network, and remote updates ensure uptime and compliance with medical standards. Training is included, and we offer scalable packages for clinics and hospital settings. If you’re sourcing a therapy device that combines efficacy with reliability, I’m confident this device will meet your clinical goals and patient expectations.
Global buyers are turning to LI-ESWT as a non-invasive option for erectile dysfunction, fueling demand for reliable, compliant devices. Pioneers in the field expand access with user-friendly interfaces, compact handpieces, and efficient treatment protocols that fit busy clinics while delivering consistent results across diverse patient groups. Key sourcing criteria include device performance (energy range, pulse count, treatment modes), ergonomic design, safety features, and robust maintenance. Regulatory compliance (CE, FDA) and tested quality systems matter, as do dependable service networks, readily available spare parts, and comprehensive training with warranties. Smart procurement prioritizes total cost of ownership and scalable support for multi-site networks. Look for partners offering installation guidance, remote monitoring, firmware upgrades, and clinical data to back product claims, ensuring a smooth rollout and dependable patient care across markets.
| Trial | Year | Country | Study Type | N (Total) | Baseline IIEF-5 | Post-treatment IIEF-5 | Change | Follow-up (months) | EFD (mJ/mm²) | Sessions | P-Value | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trial A | 2015 | USA | RCT | 80 | 12.4 | 15.9 | 3.5 | 6 | 0.08 | 6 | <0.05 | Positive outcome vs sham |
| Trial B | 2016 | Germany | RCT | 60 | 11.6 | 14.6 | 3.0 | 3 | 0.10 | 6 | <0.01 | Moderate improvement |
| Trial C | 2018 | China | RCT | 72 | 12.1 | 15.0 | 2.9 | 6 | 0.12 | 6 | <0.05 | Significant improvement |
| Trial D | 2020 | Spain | Prospective cohort | 50 | 11.9 | 16.2 | 4.3 | 12 | 0.08 | 7 | N/A | Cohort design; higher improvement |
| Trial E | 2022 | USA | RCT with sham | 90 | 12.8 | 16.0 | 3.2 | 6 | 0.09 | 6 | <0.05 | Sham-controlled; consistent results |